MORE Clinical Evidence in Hip Fracture:
ARIXTRA—Protection That Continues After Hospital Discharge

The Risk of VTE Persists After Hospital Discharge

Extending Therapy With ARIXTRA After Hospital Discharge

Total VTE Reduced to Just 1.4% (P<.001)^*

Symptomatic VTE Reduced to Just 0.3% (P=.02)^*

^*The primary efficacy outcome was VTE occurring during the double-blind period (DVT detected by mandatory bilateral venography or documented symptomatic DVT or PE).

• In this double-blind study, patients received either ARIXTRA 2.5 mg SC qd or placebo for 21 ± 2 days. All patients had previously received ARIXTRA for 7 ± 1 days.

In this hip fracture study, extended prophylaxis with ARIXTRA for 3 weeks showed no significant difference in serious adverse events vs placebo

• Incidence of major bleeding was 2.4% (8/327) for ARIXTRA and 0.6% (2/329) for placebo (P=NS)

Click here for important safety information.

Please see full prescribing information, including BOXED WARNING for Spinal/Epidural Hematomas.